Search clinical trials for: Seasonal Influenza Vaccine (MF59C.1)

Total 1404 results

Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

Seasonal Influenza

Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
Bill & Melinda Gates Medical Research Institute
Iqvia Pty Ltd

Withdrawn

Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion

Influenza
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
University of Rochester
National Institutes of Health (NIH); Dartmouth-Hitchcock Medical Center

Completed

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Influenza

United States
Center for Disease Prevention and Control of Beijing...

Completed

Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military

Influenza

China
Liquidia Technologies, Inc.
Children's Hospital Medical Center, Cincinnati; Accelovance

Completed

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 (LIfT)

Influenza

United States
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine

Influenza

Hungary
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Influenza

United States
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

Influenza

United States
Butantan Institute

Completed

Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine

Influenza

Brazil
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
ModernaTX, Inc.

Active, not recruiting

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (IGNITE P303)

Seasonal Influenza

United States
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Seasonal Influenza

Spain, United States, Denmark, Poland, United Kingdom, Germany, Canada, Taiwan, Bulgaria, Netherlands, Estonia
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Seasonal Influenza

Philippines, Australia, Colombia, Argentina, Panama
Ology Bioservices

Completed

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Influenza

United States
University of Rochester

Completed

Influenza Immunity in Children

Influenza

United States
Centers for Disease Control and Prevention, China

Unknown

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Influenza | Swine-origin A/H1N1 Influenza

China
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Influenza

United States
Oriol Manuel
University of Zurich; University Hospital, Geneva; University Hospital, Basel... and other collaborators

Completed

Reducing the Burden of Influenza After Solid-Organ Transplantation (STOP-FLU)

Influenza | Organ Transplantation

Switzerland, Spain
Clifford Craig Medical Research Trust
Johns Hopkins Bloomberg School of Public Health; Monash University; University... and other collaborators

Unknown

Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Challenge in the Elderly

Heterologous Effects of Vaccines

Australia
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons

Influenza

Hungary
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)

Influenza

Austria, Germany, Poland
National Institute of Allergy and Infectious Diseases...

Completed

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

Influenza | Influenza Immunisation

United States
Butantan Institute

Completed

Active Surveillance for Adverse Events Following Immunization With the Influenza Vaccine Produced at Butantan Institute (FLU-05-IB)

Influenza Vaccines

Brazil
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Influenza | Pandemic Influenza

Austria, Germany
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Seasonal Influenza

United States
Vaccitech (UK) Limited
University of Oxford

Terminated

Improved Novel VaccIne CombinaTion InflUenza Study (INVICTUS)

Influenza

United Kingdom
University of Pennsylvania
National Institute of Allergy and Infectious Diseases (NIAID); Stanford University and other collaborators

Recruiting

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

Influenza, Human

United States
Centers for Disease Control and Prevention, China

Completed

Persistence of Immune Response After Vaccination With Influenza Vaccine

Influenza, Human | Immunisation Reaction

China
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects

Influenza

Italy
Johns Hopkins Bloomberg School of Public Health
Columbia University; Sanofi Pasteur, a Sanofi Company; Institute of Epidemiology... and other collaborators

Completed

Pregnancy, Arsenic and Immune Response (PAIR)

Influenza | Vaccine Response Impaired | Micronutrient Deficiency | Arsenic--Toxicology | Immunologic Disorders Complicating Pregnancy

Bangladesh
Queen Saovabha Memorial Institute

Completed

Two-site Intradermal Influenza Vaccination in Elderly

Influenza

Thailand
Abramson Cancer Center at Penn Medicine

Recruiting

BRCA1/2 Flu Vaccine

BRCA1 Mutation | BRCA2 Mutation

United States
Butantan Institute

Completed

Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018) (FLU-06-IB)

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Orthomyxoviridae Infections | Physiological Effects of Drugs | Vaccines

Brazil
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

Influenza | Seasonal Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza, Vaccine

Germany
Tel-Aviv Sourasky Medical Center

Unknown

Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine

Rheumatoid Arthritis | Cellular Immune Response

Israel
University Health Network, Toronto

Completed

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Transplantation | Influenza Vaccines
Novartis Vaccines

Completed

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

Seasonal Influenza

Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

Interpandemic Influenza

Italy
PATH
Centers for Disease Control and Prevention; Institut de Recherche pour le Developpement

Completed

Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa

Influenza

Senegal
Stanford University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

MELAS Syndrome

United States
National Centre for Epidemiology, Hungary
Netherlands Vaccine Institute; National Public Health Institute, Finland

Unknown

Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines (FLUSECUOEKH1)

Healthy Volunteers

Hungary
Pfizer

Completed

Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

Respiratory Syncytial Virus

Australia
Altimmune, Inc.
Optimal Health Research

Completed

Immune Response Following Seasonal Influenza Vaccination

Influenza

United States
Novartis Vaccines

Completed

Immunogenicity and Safety of V70P5 Revaccination Subjects

Influenza

Finland
Sinovac Biotech Co., Ltd

Completed

Phase IV Clinical Trial of an Influenza Split Vaccine Anflu

Influenza
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects

Influenza

Germany

Search clinical trials for: Seasonal Influenza Vaccine (MF59C.1)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations